Profile data is unavailable for this security.
About the company
Alimera Sciences, Inc. is a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic retinal pharmaceuticals. It is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. ILUVIEN is an intravitreal implant that treats patients by delivering a continuous micro dose of the corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. ILUVIEN is inserted into the back of the patient's eye in a non-surgical procedure employing a device with a 25-gauge needle, which allows for a self-sealing wound. DME is also treated by laser photocoagulation, a retinal procedure in which a laser is used to apply a burn.
- Revenue in USD (TTM)80.75m
- Net income in USD-21.39m
- Incorporated2003
- Employees159.00
- LocationAlimera Sciences IncSTE 290, 6120 WINDWARD PARKWAYALPHARETTA 30005United StatesUSA
- Phone+1 (678) 990-5740
- Fax+1 (678) 990-5744
- Websitehttps://alimerasciences.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alpha Tau Medical Ltd | 0.00 | -29.16m | 169.30m | 121.00 | -- | 2.00 | -- | -- | -0.4203 | -0.4203 | 0.00 | 1.21 | 0.00 | -- | -- | 0.00 | -25.63 | -- | -26.99 | -- | -- | -- | -- | -- | -- | -- | 0.0623 | -- | -- | -- | 13.64 | -- | -- | -- |
bluebird bio Inc | 21.73m | -91.17m | 173.09m | 323.00 | -- | 0.4373 | -- | 7.97 | -0.7446 | -0.7446 | 0.2139 | 2.08 | 0.0383 | -- | -- | 67,263.16 | -16.08 | -33.02 | -21.50 | -37.14 | -10.08 | 19.44 | -419.62 | -4,044.31 | 1.42 | -- | 0.00 | -- | -1.77 | -36.71 | 52.62 | -- | -26.66 | -- |
Greenwich Lifesciences Inc | 0.00 | -8.89m | 180.30m | 3.00 | -- | 26.85 | -- | -- | -0.6921 | -0.6921 | 0.00 | 0.5215 | 0.00 | -- | -- | 0.00 | -86.87 | -36.43 | -89.30 | -38.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.63 | -- | -- | -- |
Alimera Sciences Inc | 80.75m | -21.39m | 181.15m | 159.00 | -- | 3.92 | -- | 2.24 | -2.16 | -2.16 | 3.17 | 0.8819 | 0.8235 | 6.22 | 2.98 | 507,886.80 | -20.53 | -19.08 | -29.94 | -27.37 | 86.58 | 86.80 | -24.93 | -19.55 | 2.31 | -0.1919 | 0.5835 | -- | 49.19 | 11.62 | -18.14 | -- | 236.53 | -- |
P3 Health Partners Inc | 1.27bn | -57.77m | 182.59m | 400.00 | -- | 0.4741 | -- | 0.1442 | -0.6494 | -0.6494 | 13.37 | 1.22 | 1.46 | -- | 13.23 | 3,165,938.00 | -21.46 | -- | -96.06 | -- | 2.50 | 0.1781 | -14.72 | -56.93 | -- | -10.33 | 0.1999 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
Mediwound Ltd | 18.69m | -6.72m | 182.91m | 100.00 | -- | 5.62 | -- | 9.79 | -0.768 | -0.768 | 2.07 | 3.43 | 0.3209 | 6.28 | 2.87 | 186,860.00 | -11.53 | -24.48 | -14.35 | -32.92 | 19.15 | 43.27 | -35.94 | -38.43 | 4.33 | -- | 0.1674 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
Kodiak Sciences Inc | 0.00 | -260.49m | 185.45m | 111.00 | -- | 0.6974 | -- | -- | -4.97 | -4.97 | 0.00 | 5.06 | 0.00 | -- | -- | 0.00 | -45.46 | -31.73 | -49.53 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
X4 Pharmaceuticals Inc | 0.00 | -101.17m | 185.57m | 93.00 | -- | 3.62 | -- | -- | -0.6026 | -0.6026 | 0.00 | 0.3052 | 0.00 | -- | -- | 0.00 | -66.81 | -61.53 | -78.53 | -69.20 | -- | -- | -- | -13,288.93 | -- | -- | 0.5164 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
Cardiff Oncology Inc | 488.00k | -41.47m | 189.13m | 31.00 | -- | 2.71 | -- | 387.55 | -0.9281 | -0.9281 | 0.0109 | 1.56 | 0.0049 | -- | 0.9216 | 15,741.94 | -41.90 | -31.24 | -46.15 | -33.56 | -- | -- | -8,492.01 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
Outlook Therapeutics Inc | 0.00 | -51.50m | 189.54m | 24.00 | -- | -- | -- | -- | -3.99 | -3.99 | 0.00 | -1.87 | 0.00 | -- | -- | 0.00 | -122.07 | -214.69 | -441.62 | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -- | 3.00 | -- | -- | -- | 10.70 | -- | -- | -- |
Rigel Pharmaceuticals Inc | 116.88m | -25.09m | 191.19m | 147.00 | -- | -- | -- | 1.64 | -0.1444 | -0.1444 | 0.6717 | -0.1638 | 0.9295 | 0.9713 | 3.30 | 795,115.60 | -19.95 | -28.82 | -37.72 | -47.26 | 93.92 | 97.88 | -21.47 | -35.76 | 1.76 | -4.45 | 1.93 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
Atossa Therapeutics Inc | 0.00 | -30.09m | 191.72m | 10.00 | -- | 2.11 | -- | -- | -0.2386 | -0.2386 | 0.00 | 0.7264 | 0.00 | -- | -- | 0.00 | -27.39 | -29.97 | -28.80 | -32.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.62 | -- | -33.90 | -- |
Holder | Shares | % Held |
---|---|---|
Caligan Partners LPas of 31 Dec 2023 | 16.84m | 32.16% |
Velan Capital Investment Management LPas of 31 Dec 2023 | 13.61m | 25.99% |
Stonepine Capital Management LLCas of 31 Dec 2023 | 4.00m | 7.64% |
Boothbay Fund Management LLCas of 31 Dec 2023 | 3.20m | 6.11% |
Altium Capital Management LPas of 31 Dec 2023 | 2.66m | 5.08% |
AIGH Capital Management LLCas of 31 Dec 2023 | 2.23m | 4.25% |
Clearline Capital LPas of 31 Dec 2023 | 2.17m | 4.14% |
Morgan Stanley & Co. LLCas of 31 Dec 2023 | 910.83k | 1.74% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 626.37k | 1.20% |
Worth Venture Partners LLCas of 31 Dec 2023 | 556.64k | 1.06% |